Corporate News
Therma Bright Partners With Afero To Make AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Smart-Enabled
Silicon Valley tech firm brings encrypted solution for tracking Canadian developer’s 15-minute Covid19 rapid antigen test for point of care, and then at-home testing Toronto,
Therma Bright’s AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P.1 and P.2 and the UK B.1.1.7 Variants
Toronto, Ontario–(Newsfile Corp. – April 22, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva
Therma Bright Announces EU-CE Approval for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test and Conditional Sale for 100,000 CE-only AcuVid(TM) Test Kits
New global distribution partner McWilliams Collective secures test kit order from European client Toronto, Ontario–(Newsfile Corp. – April 19, 2021) – Therma Bright Inc. (TSXV:
Therma Bright Provides Update on Brazilian Performance Study of its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – April 13, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva
Therma Bright Receives IRB Approval and Submits Application to Health Canada to Begin Clinical Study for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – March 25, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva
Therma Bright Partners with Ridge Global to Expand Its United States and Global Reach
Toronto, Ontario–(Newsfile Corp. – March 24, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVidTM COVID-19 Rapid Antigen Saliva Test
Therma Bright Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – March 18, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
A Market ‘Game Changer’ for Rapid COVID-19 At-Home Testing?
While we can finally see light at the end of the tunnel in the fight against COVID-19, the global pandemic has invariably changed how we
Therma Bright Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – March 11, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – February 26, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – February 26, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased to announce
Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test
Toronto, Ontario–(Newsfile Corp. – January 25, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma Bright” or the “Company”), a progressive medical device technology company announces that it
Therma Bright Partners With Afero To Make AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Smart-Enabled
Silicon Valley tech firm brings encrypted solution for tracking Canadian developer’s 15-minute Covid19 rapid antigen test for point of care, and then at-home testing Toronto,
Therma Bright’s AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P.1 and P.2 and the UK B.1.1.7 Variants
Toronto, Ontario–(Newsfile Corp. – April 22, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva
Therma Bright Announces EU-CE Approval for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test and Conditional Sale for 100,000 CE-only AcuVid(TM) Test Kits
New global distribution partner McWilliams Collective secures test kit order from European client Toronto, Ontario–(Newsfile Corp. – April 19, 2021) – Therma Bright Inc. (TSXV:
Therma Bright Provides Update on Brazilian Performance Study of its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – April 13, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva
Therma Bright Receives IRB Approval and Submits Application to Health Canada to Begin Clinical Study for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – March 25, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva
Therma Bright Partners with Ridge Global to Expand Its United States and Global Reach
Toronto, Ontario–(Newsfile Corp. – March 24, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVidTM COVID-19 Rapid Antigen Saliva Test
Therma Bright Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – March 18, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
A Market ‘Game Changer’ for Rapid COVID-19 At-Home Testing?
While we can finally see light at the end of the tunnel in the fight against COVID-19, the global pandemic has invariably changed how we
Therma Bright Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – March 11, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – February 26, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test
Toronto, Ontario–(Newsfile Corp. – February 26, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased to announce
Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test
Toronto, Ontario–(Newsfile Corp. – January 25, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma Bright” or the “Company”), a progressive medical device technology company announces that it
